On Thursday, Alzamend Neuro Inc (NASDAQ:ALZN) entered into a Securities Purchase Agreement with an institutional investor for the purchase and sale of 50 shares of its Series A Convertible Preferred Stock, the stated value of $10,000 per share in a registered direct offering, for $500,000. Also Read: EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year Additionally, the Investor agreed to purchase up to an additional 2,450 Preferred Shares, of which 50 shares will be purchased at the initial closing ...